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Abstract
Anorexia Nervosa (AN) is characterized by a self-imposed starvation and is often
accompanied by excessive exercise that results in severe malnutrition and sometimes death.
Behavioural and pharmacological treatments of AN need to be improved. In rats, acute 3 h
daytime wheel access suppresses ad lib feeding over the subsequent night relative to no wheel
controls, a phenomenon that has been suggested as an animal model of AN. This acute wheel
induced feeding suppression (WIFS), can be induced reliably when rats are given limited wheel
access exposure during the light cycle (Lattanzio & Eikelboom, 2003). The acute WIFS is useful
because it can be used to test the effects of pharmacological agents, in a paradigm where the
duration of wheel running and its effects are tightly defined. Chronic chlorpromazine injections
can minimize the severity of activity anorexia (AA) procedure (Routtenberg, 1968), a related rat
model of AN (Epling, Pierce & Stephan, 1983), by attenuating wheel running. Experiment 1
tested the acute effects of a one-time chlorpromazine injection (2 mg/kg IP) on the acute WIFS
in 40 adult male rats. Animals were divided into five treatment groups (n=8): drug before wheel
access (DW); drug after wheel access (WD); drug with locked wheel access (DNW); saline with
locked wheel access (SNW); and saline with wheel access (SW). Half of each of the three
control groups (DNW, SNW and SW) received injections before wheel access and half were
injected after the wheel access period. Experiment 2 followed the same procedure except a
broader range of chlorpromazine doses was tested (0.25, 0.50, 1 and 2 mg/kg). Both studies show
that while chlorpromazine (at 1 and 2 mg/kg) did not attenuate feeding or wheel running, it
blocked the acute WIFS. At doses of 0.25 and 0.50 mg/kg chlorpromazine had no effect.

iv
Because the pharmacological profile of chlorpromazine implicates the serotonin, histamine and
dopamine systems in the acute WIFS (and potentially AN), future work should look at drugs
with more specific modes of action to identify which neurotransmitter systems may be involved.
The acute WIFS procedure may be useful for screening potential drug treatments for AN, where
exercise is often elevated and feeding is suppressed.
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Chlorpromazine and Wheel Running 1
Anorexia nervosa (AN) is a disorder that is characterized by excessive weight loss caused
at least partially by reduced eating. Often, this condition is exacerbated by a constant general
hyperactivity and compulsion to exercise (Attia & Walsh, 2009; Bergh, Erisson, Lindberg &
Sodersten, 1996; Casper, 2006). It has been observed that up to 85% of AN patients exercise to
excessive levels throughout the course of the disorder (Davis, 1997) and some argue that the
relationship between excessive activity and reduced feeding is a key feature of AN.
Current treatments for AN, most of which are behavioural in nature, are not very
effective. Of all patients treated, only 46% fully recover, 34% improve and 20% develop a
chronic form of the disease that, in many cases, leads to death (Steinhausen, 2002). Given the
unfavourable prognosis of AN patents, it is evident that clinicians need to look beyond the
traditional 'behavioural' treatment strategies and into other domains, such as the biochemical.
To explore the biochemical substrates of human disease, researchers commonly turn to animal
models.
With respect to AN, many wheel running animal models exist, all of which examine the
relationship between feeding and exercise when it becomes counterintuitive. One possible
advantage of such models is that they allow for the study of AN in the absence of the
psychological and social factors, which may make our understanding of the disease difficult in
humans. Once it is clear how feeding and exercise interact in AN, researchers will be in a
position to study how psychological factors might contribute to the development and
maintenance of this disease.
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Wheel Running Models of Anorexia Nervosa
When a rat is given continuous access to a running wheel, it will run and gradually
escalate its running from about 1 km on the first day up to 5-6 km over a period of a few weeks
(Eikelboom & Mills, 1988). One interesting consequence of wheel introduction is a 25% selfimposed suppression in feeding lasting about 7 to 10 days and a chronic reduction in weight
(Alfonso & Eikelboom, 2003). This has been labelled as the wheel induced feeding suppression
(WIFS). This phenomenon is counterintuitive because the animals expend more calories running
and consume less food than non-wheel controls. It has been proposed that this could function as
a model of an important aspect of AN (Lattanzio & Eikelboom, 2003).
The animal model of AN that has attracted the most attention is the activity anorexia
(AA) procedure (Casper, Sullivan & Tecott, 2008; Epling, Pierce & Stephan, 1983). This
procedure is similar in some ways to the WIFS paradigm. In the AA procedure, wheel
introduction and food restriction (usually 1 hour of food access a day) are introduced
simultaneously and result in reduced feeding (relative to food restricted non-wheel controls) and
increased running (relative to non-deprived controls) which proves fatal for rats within a few
days (Routtenberg & Kuznesof, 1967). The interpretation of AA is complicated by a number of
factors inherent to the procedure. Firstly, there is a learning complication in that animals must
adapt to the experimenter-imposed feeding schedule. Thus, food intake generally increases over
the first number of days and over cycles of this procedure in a manner that indicates learning
(Boakes & Dywer, 1997; Hampstead et al, 2003; Lett et al, 2001; Pare et al., 1985). Secondly,
with food deprivation, wheel running increases significantly (relative to ad lib fed rats) and thus
energy expenditure is increased (Routtenberg & Kuznesof, 1967). This occurs even if the wheel
is not novel (Exner et al., 2000; Nergardh et al., 2007). Lastly, at wheel introduction feeding is
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suppressed both with ad lib and restricted food access (Alfonso & Eikelboom, 2003; Routtenberg
& Kuznesof, 1967). The feeding suppression induced by the wheel is temporary, both with ad
lib feeding (Afonso & Eikelboom, 2003) and in the AA procedure (Hampstead et al., 2003).
The problem in the activity anorexia procedure seems to be that animals do not have enough
energy reserves to adapt to the various changes before the onset of starvation. It is not clear how
or if these three factors are connected, or how they interact in the AA procedure, but they
ultimately may all be important in AN. What is apparent is that the WIFS, because it does not
involve food deprivation, provides a simpler model that may address specific aspects of the
feeding-exercise relationship.
The WIFS seen with voluntary running and ad lib feeding, has many attributes that make
it a useful animal model of the exercise feeding relationship in AN. Our model is considered to
have obvious face validity for AN (Willner, 1990), as it reflects the negative relationship
between exercise and feeding found in the human condition (Attia & Walsh, 2009; Bergh &
Sodersten, 1996; Casper, 2006). This isomorphic model of AN (Smith, 1989) reflects many
aspects of the human disorder without specifying its etiology or mechanisms, which remain
largely unknown but are easier to explore in the animal model. The most obvious benefit to the
WIFS model is that all of the changes in feeding and running are intrinsically motivated, not
externally imposed by an experimenter. The rat model shows a similar developmental profile to
that seen in human AN. For example, prepubescent rats (less than 32 days old), even though
they run as far as (or further than) their adult counterparts, do not show the typical feeding
suppression observed when adolescent (36 - 41 days old) and adult (51+ days old) rats are given
the opportunity to run (Dalton-Jez & Eikelboom, unpublished work). This highlights the
potential for the WIFS as a model to study AN.
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One very important characteristic of the WIFS model is that it can be elicited when rats
are given short-term access to a wheel. It has been shown that 2 h of wheel access during the
light cycle is enough to trigger this feeding suppression over the next night (Lattanzio &
Eikelboom, 2003). One key benefit of testing the effects of limited daytime wheel access on
feeding is that both the wheel and no wheel groups can feed without distraction during the dark
cycle, when most eating occurs.
This acute WIFS may prove a valuable procedure for determining the neurochemical
systems involved in this paradoxical exercise-feeding relationship. Using an acute WIFS model,
a drug can be given to an animal before, after, or in the absence of, short term daytime wheel
access, permitting an evaluation of the drug's effect on running, feeding, and the running-feeding
interaction without the complication of constant wheel access. As drug tests in animal models
have long been suggested as useful for preclinical drug evaluations (Mc Kinney, 1974), this
procedure could ultimately lead to our understanding of the biochemical compounds and
processes involved in AN and potential pharmaceutical treatments. The question that remains
then, is what class of drugs should be the first explored in the acute wheel running model?
Foundational research, conducted in the 1960s and 70s with the AA procedure, suggests that the
antipsychotics might be a good place to start.

Experimental Foundations
The deadly relationship between ad lib wheel running and restricted (1 h per day)
feeding in rats was first discovered in 1954 by Hall and Hanford. Soon after, researchers began
to try and uncover the neural mechanisms behind AA. Initial work tested the effect of the
antipsychotic chlorpromazine (CPZ) and the sedative pentobarbital (PTB), on the survival rates
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of rats in the AA procedure. Routtenberg and Kuznesof (1967) injected rats daily with either
CPZ (1 mg/kg), pentobarbital (4 mg/kg) or saline immediately after the 1 h feeding period in the
AA procedure. Food consumption, body weight and wheel running were measured daily.
Results indicated that pentobarbital was not helpful in improving survival. Rats injected with
this agent ran excessively, did not adapt to food restriction, lost weight and died (as did noninjected controls). Chlorpromazine, on the other hand, was effective in significantly reducing
wheel running and improving survival compared to saline injected control rats, allowing animals
to stabilize body mass. Specifically, CPZ injected rats survived for the entire duration of the
study and ran maximally 1500 wheel turns, while the saline injected controls reached exhaustion
by day 8 and ran roughly 5000 wheel turns.
Although CPZ at 1 mg/kg improved survival, reducing wheel running compared to the
saline group, not all rats injected were protected from starvation. In fact, 25% of them still
perished. To determine the optimum dose of CPZ required to ensure survival of all AA rats,
Routtenberg (1968) replicated his first experiment using a 2 mg/kg dose of CPZ. Rats were
given daily IP injections over the course of the study. After 8 days of baseline, animals were put
on a restricted (lh/day) diet and given ad lib access to either locked or unlocked wheels for 8
days. Again, wheel running, body weight and food consumption were measured. Data showed
that 2 mg/kg injections of CPZ improved survival rates, and even more so than those injected
with 1 mg/kg. Rats injected with 2 mg/kg ran significantly less (about 1000 revolutions by day
12) than those with only 1 mg/kg (roughly 3000 revolutions by day 12) and weighed about 25 g
more. Interestingly though, the group injected with the higher dose of CPZ and with the higher
survival rate, ate less than the 1 mg/kg group over the first 10 days of the experiment. One
explanation for this might be that, at higher doses, CPZ produces a conditioned taste avoidance
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(CTA), as described by Parker (2003), that enhances the feeding suppression observed when rats
are introduced to the AA paradigm.
Taken together, these findings suggest that CPZ, a typical antipsychotic, can help animals
cope in the AA paradigm by reducing activity. They also suggest that 2 mg/kg might be the
optimum dose, as it seems to be the minimum required to ensure that 100% of the animals
survive. These findings make it tempting to suggest CPZ as a potential treatment for AN,
however it would be premature to do so. Although Routtenberg's studies answer many questions
about the effect of CPZ on activity in the AA procedure, it is unclear how feeding is effected.
This is especially true since the animals are externally food deprived, unlike in AN where the
feeding suppression is self imposed. Furthermore, it is not clear why the CPZ injected rats ate
less than the saline injected group. Was it because CPZ directly effected feeding? Or was it
because CPZ impaired the animal's ability to learn? Unfortunately it is impossible to tease these
two possibilities apart using the AA model alone. Moreover, as wheel access is continuous
(except for feeding time) it is not clear when the drug should be administered to have the most
effect, especially since CPZ's half life is known to range from 16 - 30 h when injected in
humans (Yeung et al., 1993). In these early studies by Routtenberg's group, CPZ or saline was
injected immediately after the 1 hour feeding period. Thus, administration was far removed from
the next meal and could have resulted in learned taste avoidance (Parker, 2003). This could
indirectly prevent a recovery of feeding, making it difficult to distinguish the avoidance from
drug-induced reduction.
To address the limitations of the AA model and to answer the lingering questions from
Routtenberg's important groundwork, it would be interesting to explore the effects of CPZ on the
acute WIFS model. Using this paradigm the effect of CPZ on running, feeding and the running-
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feeding interaction could be specifically identified. By testing similar doses to those used by
Routtenberg we have a reference data set to which we can compare and contrast. This presents a
great opportunity for us to build on historical work and take it to the next level. One point worth
mentioning is the fact that during Routtenberg's time little was known about the effects of
antipsychotics on feeding and weight gain. Today however, this is not the case and it may be
useful to discuss the affects of antipsychotics, specifically chlorpromazine, on weight.

Chlorpromazine
Chlorpromazine (2-chloro-10-(3-dimethylaminopropyl-phenothiazine) represents one of
the earliest known and clinically prescribed antipsychotics. In 1955 it was approved in the
United States and the effect of this drug in emptying mental hospitals has been compared to that
of penicillin on infectious disease (Turner, 2007).
CPZ affects a variety of receptors in the central nervous system, having
antidopaminergic, anti antiserotonergic and antihistaminic properties which are discussed in
detail below. Interestingly, CPZ tends to have a higher affinity at serotonin receptors than at
dopamine receptors, which is the opposite effect of most other typical antipsychotics. Therefore,
CPZ behaves more like an atypical antipsychotic in terms of its dopamine and serotonin activity
(McKim, 2007). CPZ could help treat patients with AN by reducing the rewarding aspects of
excessive exercise and starvation, through antagonizing the Dl, D2, D3 and D4 receptors
(Friedman, 1996), and by increasing appetite and feeding through blocking the HI and 5-HT2C
receptors, respectively (Ravussin, Lillioja & Knowler, 1988; Gothelf, et al., 2002).
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Antipsychotic Pharmacology: Antipsychotic action and Weight Gain
Antipsychotic drugs (also referred to as neuroleptics) are a group of psychoactive
compounds that treat psychosis. Antipsychotics are lipophilic antagonists that effect behavior by
binding to postsynaptic dopamine, serotonin and histamine receptors (amongst others) in
different regions of the brain. Each antipsychotic has a slightly different pharmacologic profile
but all block D2 receptors in the dopamine pathway causing dopamine to have less of an affect.
Excess release of dopamine in the mesolimbic pathway has been correlated with psychotic
disorders, such as schizophrenia, and these drugs are very effective at controlling symptoms
(Friedman, 1996). In fact, an almost perfect correlation exists between the therapeutic dose of an
antipsychotic and the drugs affinity for the D2 receptor. Therefore, a weak antagonist requires a
larger dose to control psychotic symptoms and vice versa (Jones & Pillowsky, 2002).
The first class of antipsychotics (known as typical antipsychotics) involved the discovery
of CPZ's affects in the 1950s. These early drugs, although effective in reducing psychotic
symptoms, produce a number of serious side effects including weight gain. A second generation
of drugs, called the atypical antipsychotics, has since been developed. Atypical antipsychotics,
such as olanzapine, treat psychosis with fewer side effects but still lead to obesity (Allison et al.,
1999).
Antipsychotic induced weight gain is caused by both a reduction in energy expenditure
(Ravussin et al., 1988) and an increase in food intake (Gothelf et al., 2002). Support for this
comes from reports that demonstrate lower than predicted resting energy expenditure in people
taking antipsychotic drugs compared to age matched healthy and schizophrenic controls not
taking the drug (Sharpe et al., 2005). A recent study demonstrated that patients taking clozapine
(an atypical antipsychotic) burn 20% less energy and consume 20% more calories than the World
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Health Organization's daily recommendations (Sharp et al., 2006), suggesting it as a possible
treatment for AN.
Two receptors that are robustly associated with weight are the serotonin 2C (5-HT2C)
and histamine 1 (HI) receptors. Chronic agonistic activation of the serotonin receptor decreases
feeding and feeding behavior (De Vry & Schreiber, 2002), while blocking the receptor
chronically induces food intake, despite satiety, leading to weight gain (Meguid et al.,2000). It
is thought that antipsychotics lead to weight gain by chronically antagonizing the central 5HT2C receptors which cause patients to overeat, regardless of the sensation of satiety (Reynolds,
Hill & Kirk, 2006) Histamine receptors are also linked to appetite. Appetite is increased by the
chronic antagonism of the central HI receptors (Wirshing et al., 1999). Interestingly, the
different receptor affinity of antipsychotics to 5-HT2C and HI are correlated with their weight
gain potential. For instance, clozapine and olanzapine (typical antipsychotics), which have the
highest affinity for 5-HT2C and HI induce the greatest weight gain. In contrast, Risperidone
(another typical antipsychotic) has a lower affinity for the 5-HT2C and HI receptors, causing
lesser weight gain (Virk et al., 2004). Although the 5-HT2C and HI receptors are the most
robust biological factors contributing to weight gain, the role of other neuroendrocrine factors
such as ghrelin, leptin, orexin and prolactin is unclear (Rege, 2008). Further research is required
to uncover their mechanisms and thus we will leave them out of further discussion.
To date, there is an enormous body of research identifying the medical properties of
antipsychotics and their effects on brain chemistry and behavior (see Parraga, 2007 for a
comprehensive example) but it is unclear how these drugs effect energy balance in patients with
AN. To gain insight into this question (and to better understand the neural substrates of the
wheel running rat model) the effects of CPZ on feeding, exercise and the interaction of these two
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variables in the acute WIFS paradigm will be investigated.

The Current Study
It has long been evident that antipsychotic drugs commonly induce weight gain as a side
effect (Allison et al., 1999). There has been speculation as to whether these drugs could help in
the initial phases of AN treatment, because of their weight gain inducing qualities and the
possible alleviation of associated psychological symptoms (fear of fatness, misperception of
body mass). Recently, a randomized, double blind, placebo controlled trial of olanzapine, an
atypical antipsychotic, was conducted using female AN patients as participants (Bissada et al.,
2008). Olanzapine use resulted in increased weight gain and lessening of obsessive symptoms
and has been suggested as a valuable option for the initial, short term phase of treatment. In light
of these results, it would be prudent to test antipsychotics in the acute WIFS procedure.
In the current study CPZ, the typical antipsychotic, was evaluated using the acute WIFS
procedure. This was the first of many drugs tested in the activity anorexia procedure
(Routtenberg, 1968; Routtenberg & Kunzesof, 1967; Woods & Routtenberg, 1971). Chronic
administration of CPZ in the activity anorexia paradigm reduces wheel running and so indirectly
decreases the severity of the procedure. While these studies do provide a model in which to test
drugs, the model is limited by the aforementioned complications of the AA procedure. In the
current study, the acute WIFS model is used to evaluate the impact of acute CPZ on feeding,
running, and the WIFS. Based on chronic work, it may be that CPZ (and similar drugs) directly
stimulates or suppresses feeding which would then be evident in non-wheel controls.
Alternatively, it may directly reduce activity and thus indirectly prevent the WIFS, tested by
comparing groups given the drug before or after the limited wheel exposure. A third more
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interesting possibility is that the exercise-feeding suppression dyad may be prevented by this
drug. Such a drug would then target the relationship between running and feeding without
increasing eating in non-exercising control animals or decreasing exercise, specifically removing
the threat of this harmful relationship. If this dyad is an important aspect of the etiology of AN,
it would suggest this class of drugs might prove useful in treatment of this puzzling disorder.

Experiment 1: As published by Adams, Parfeniuk & Eikelboom, 2009
Method
Subjects
Fourty male Sprague-Dawley rats (Charles River Canada, St. Constant, Quebec, Canada)
weighing 200-225 g (47-49 days old) upon arrival were housed individually in standard shoebox
cages (20 x 24 x 45 cm) and maintained on a 12 hour light/dark cycle, with lights on at 0700
(7:00 AM). Colony conditions were kept stable (50% relative humidity, 21-22 °C), and food and
tap water were available ad libitum throughout the study. All experimental procedures were
approved by the Wilfrid Laurier University Animal Care Committee which follows the policies
and guidelines of the Canadian Council on Animal Care.
Apparatus
Wheel access was given in Nalgene™ running wheels (33 cm diameter and 11 cm wide)
inserted in standard shoebox cages. These wheels could be locked using two paper clamps
clipped between the rungs on the outside of the Nalgene wheel to prevent wheel turning. Wheel
turns were counted to a resolution of 1 s using a magnetic closure system and the VitalView™
Minimitter Co. Ltd. software package.
Drug and doses
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Chlorpromazine solution (CPZ, as chlorpromazine hydroxide, Sigma Aldrich, St. Louis,
MO) was prepared fresh on each injection day in sterile isotonic saline at a dose of 2.0 mg/kg.
CPZ was injected intraperitoneally (IP) at a volume of 1 ml/kg. The control rats that did not
receive CPZ received equivalent injections of saline.

Procedure
Baseline measures of food consumption, water consumption and weight were taken daily
at about 1430 (2:30 PM). Food consumption was measured by dumping the food pellets from the
lid of each cage into separate plastic dishes and weighing them on a digital scale that was
accurate to one tenth of a gram. Daily food consumption was determined by calculating the
differences in food weight from one day to the next. Small crumbs and food particles were
ignored, as in previous work they have been found to weigh less than 1 g, and not to vary across
conditions. Rats initially received 300 g of food at the start of the experiment and were topped
up to this amount once their total available food volume fell below 200 g. Water bottles were
weighed daily, also at around 1430, and the difference from one day to the next indicated how
many ml each rat consumed. Once a bottle fell below half of its capacity (which was about 600
ml) it was topped up. Body weight was measured daily between 1430 (2:30 PM) and 1530 (3:30
PM). After 7 days of baseline, all 40 rats were moved into wheel cages for 24 h to establish a
baseline running level, measure the WIFS seen with one day of ad lib wheel access and provide
rats familiarity with the wheel. The rats were then assigned in a way to equalize for feeding
suppression (day before wheel running - the day after wheel running), distance run (wheel turns)
and body weight (g) into 5 groups of 8. Twenty-four h after the wheel exposure period rats were
rank ordered from smallest to largest in terms of their WIFS and then distributed to 1 of the 5
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treatment groups in the following manner: Rat 1 into group 1, Rat 2 into group 2, Rat 3 into
group 3, Rat 4 into group 4, Rat 5 into group 5, Rat 6 into group 1, Rat 7 into group 2, Rat 8 into
group 3 etc. After all the rats had been distributed in terms of their WIFS an analysis of variance
(ANOVA) was completed to ensure that none of the groups differed in terms of their WIFS,
wheel turns or body weight. If any groups differed at this point the animals were shifted around
using feeding and weight data until all groups were equal.
The five groups were the drug before wheel access (DW); drug after wheel access (WD);
drug with locked wheel access (DNW); saline with locked wheel access (SNW); and saline with
wheel access (SW). Half of each of the three control groups (DNW, SNW and SW) received
their injections before wheel access and half were injected after the wheel access period (a 3
group by 2 injection time ANOVA revealed no significant differences in feeding on the critical
day due to injection time, so the two sub-groups for each group were combined for the final
analysis).
Three days after the 24 h baseline wheel exposure, animals injected before wheel access
received the appropriate IP injections, either saline or CPZ, at approximately 1500 and were
placed back into their home cages. Thirty minutes after their injection (about 1530), all rats were
placed in the wheel cages, with the wheel unlocked for wheel access or locked for novel
environment only groups, and remained there for 3 h (during which food was not accessible).
The rats were then placed back in their home cages 30 min before the lights went out. Groups
that received their injection after wheel access were injected immediately after being removed
from the wheel cage. Each rat received only one injection. Food consumption over the next 22
hours was measured as the critical dependent variable.
Results
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Initial 24 h baseline access
Figure 1 shows wheel turn data over the 24 h baseline running period. Because of the
way the animals were assigned a 5 group ANOVA revealed that the experimental groups did not
differ significantly. Wheel turns in this period did not correlate with later 3 h running, or with the
decrease in feeding induced by the 24 h of this baseline wheel access.
Figure 2 shows food consumption for the day before and the day after wheel access (24
h). Data was analyzed using a 5 group by 2 day mixed ANOVA which revealed an overall
significant feeding suppression [F(l,35) = 52.26, p < .001], but again, because rats were
assigned to groups based on their feeding suppression, the groups did not differ. Rats ate 29.8 ±
.52 (SEM) g the day before the 24 h wheel access and 25.0 ± 0.58 g over the 24 h of wheel
access.

Running on injection days (3 h wheel access).
A 3 group ANOVA revealed that the wheel groups (DW, WD, SW) did not differ
significantly in their running over the three hours of wheel access, as measured in wheel turns
(see Figure 3).

Feeding after injection and 3 h wheel access.
Figure 4 depicts feeding over the 24 h after injection of CPZ or saline before or after 3 h
access to a locked or unlocked wheel. Overall, the 5 group ANOVA revealed the food
consumption of the groups differed significantly [F (4,35) = 3.82, p < 0.05]. A Newman-Keuls
post hoc test found that only the saline injected, wheel exposed rats (Group SW) ate less than the
rats in the other four groups,/* < 0.05.
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In the three wheel groups, feeding suppressions (difference between the 24 h before
wheel access and the 24 h afterwards) differed [F(2,2\) = 18.49, p < 0.001]. Again, post hoc
tests show that the SW group was responsible for this effect, being the only wheel group that
showed a feeding suppression (data not depicted).
There was also no correlation between number of wheel turns and feeding in the 24 h
after 3 h wheel exposure (for the 24 rats with wheel access the Pearson r = -0.039).

Discussion
Experiment 1 suggests that 2 mg/kg of CPZ specifically prevents the interaction of
running and feeding in the acute WIFS paradigm. This is true since CPZ did not elevate feeding
in the DNW group relative to the SNW group or reduce running in the DW group relative to the
WD group but did block the running-feeding interaction (in the DW and WD groups compared
to the SW group). These results are very interesting and suggest CPZ may be useful in
identifying the neural substrates of the WIFS (and potentially AN). Before we can begin to
understand how CPZ may act as a possible treatment for the acute WIFS paradigm and thus AN,
more questions need to be resolved: First, are these results repeatable? Second, what minimum
dose is required to observe this effect? And finally, is this a dose dependent or an "all or none"
effect? Experiment 2 was designed to answer these questions.

Experiment 2
Methods
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Subjects
Sixty-four male Sprague-Dawley rats (Charles River Canada, St. Constant, Quebec,
Canada) were housed in standard shoebox cages (20 x 24 x 45 cm) and kept on a 12 h light-dark
cycle, with lights on at 1200 (noon). Colony conditions were kept stable (50% relative humidity,
21 - 22°C), and food and tap water were available ad libitum throughout. The animals had a
history of saccharin consumption from a previous experiment and were therefore given 10 days
to acclimatize to their "non-saccharin" diets before baseline food and water measures
commenced. The animals weighed between 450 - 550 g at the start of the experiment and all
treatment groups were counterbalanced with respect to saccharin history. All experimental
procedures were approved by the Wilfrid Laurier University Animal Care Committee which
follows the policies and guidelines of the Canadian Council on Animal Care.

Apparatus
The equipment used here were the same as in Experiment 1.

Drug and doses
Chlorpromazine solution was prepared fresh on each injection day in sterile isotonic
saline at doses of 2.00, 1.00, 0.50 and 0.25 mg/kg. CPZ was injected intraperitoneally (IP) at a
volume of 1 ml/kg. The control rats that did not receive CPZ received equivalent injections of
saline.

Procedure
Baseline measures of food consumption, water consumption and weight were taken daily
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at about 1500. Food, water and wheel turn data were collected using the same procedures as in
Experiment 1. Due to equipment limitations, Experiment 2 was conducted in two equivalent
replications of 32 rats. After collecting 7 days of baseline data (food consumption [g] and body
weight [g]), rats were given 24 h of wheel access to establish baseline levels of running, measure
the WIFS seen with one day of ad lib wheel access and provide rats with familiarity to the wheel.
The rats were then randomly assigned to equalize wheel running and feeding suppression to 8
groups of 8: 2 mg/kg drug before wheel access (2-DW); 2 mg/kg drug after wheel access (2WD); 1 mg/kg drug before wheel access (1-DW); 0.5 mg/kg drug before wheel access (.5-DW);
0.25 mg/kg before wheel access (.25-DW); 2 mg/kg drug with locked wheel access (2-DNW);
saline with locked wheel access (SNW); and saline with wheel access (SW).
Three days after the 24 h baseline wheel exposure, animals injected before wheel access
received the appropriate injections, either saline or CPZ, at approximately 1800, 4 h before lights
out. Thirty minutes after their injection (about 1830), all rats were placed in wheel cages, with
the wheel unlocked for wheel access or locked for novel environment only groups, and remained
there for 3 h. The rats were then placed back in their home cages. Groups that received their
injection after wheel access were injected immediately after being removed from the wheel cage.
Each rat received only one injection. Food consumption over the next 24 h was measured as the
critical dependent variable.

Results
Initial 24 h baseline access
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Since animals were assigned to groups to equalize distance run, an 8 group analysis of
variance (ANOVA) revealed that the groups did not differ significantly in wheel turns over the
baseline day (see Figure 5). Similar to Experiment 1, the distance run over the initial 24 h wheel
access did not correlate with later 3 h running, or with the decrease in feeding induced by the 24
h wheel access.
An 8 group by 2 day mixed ANOVA looking at food consumption (g) on the test day, 24
h after the 3 h wheel exposure, revealed an overall significant effect on feeding [F(l,56) = 552.9,
p < 0.001] and that none of the treatment groups differed. This indicates that the experimental
groups were successfully balanced for their level of feeding suppression. Rats consumed 36.8 ±
0.52 (SEM) g the day before wheel access and 31.0 ± .58 g over the 24 h of wheel access (see
Figure 6).

Running on injection days (3 h access).
The 5 group ANOVA revealed that the 5 wheel groups (.25-DW, .5-DW, 1 -DW, 2-DW,
2-WD) did not differ significantly in their running over the three hours of wheel access, as
measured in wheel turns (see Figure 7). There was also no significant correlation between the
number of wheel turns and feeding in the 24 h after 3 h wheel exposure (for the 40 rats with
wheel access the Pearson r = -.167).

Feeding after injection and 3 h wheel access.
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Figure 8 shows feeding over the 24 h after injection of CPZ (at 2.00, 1.00, 0.50 or 0.25
mg/kg) or saline before or after 3 h access to a locked or unlocked wheel. Overall, the 8 group
ANOVA revealed a significant main effect on feeding [F(7,55) = 5.292, p < .001]. A NewmanKeuls post hoc test revealed that the SW group ate less than the SNW, 1-DW, 2-DW, 2-WD and
2-DNW groups and that the .25-DW and .5-DW groups ate an intermediate amount of food
compared to the SW and 2-DW/2-WD groups.

Discussion
Two mg/kg of CPZ prevented the acute WIFS, replicating the effects observed in
Experiment 1. It was also determined that a dose of 1 mg/kg may be the minimum required to
prevent a feeding change when rats gain access to the wheel. Furthermore, Experiment 2
revealed that the effects of CPZ on the acute WIFS are dose dependent (and not "all or none").

General Discussion
The Present Study
Using the WIFS, a simple model that focuses on a specific aspect of the AA procedure,
we are able to dissect some of the links between exercise and feeding. In particular this acute
WIFS procedure can be used as a simple screen to assess the acute behavioural effects of drugs,
in this case CPZ, and elucidate how the drug works to impact feeding in the WIFS. In this
procedure, the direct effect of the drug on feeding is evident in the comparison between the
saline and drug groups that did not have wheel access. In the present study it was shown that
acute injections of CPZ have do not directly effect feeding. The comparison between the two
saline groups with and with out wheel access demonstrates that the procedure supports a feeding
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suppression. Further comparison of rats receiving CPZ before or after wheel access
demonstrated that drug had no effect on acute daytime wheel running. Finally the comparison of
the CPZ wheel groups with the CPZ no wheel group demonstrated that the drug prevents the
acute WIFS.

Chlorpromazine's effect on wheel running in the Acute WIFS
Based on Routtenberg's chronic work (1967), it may be expected that the DW groups
would have run less than the SW and WD groups, but this was not the case. In fact, all wheel
groups, regardless of their injection history, ran equivalent distances. Reasons for this are not
totally clear. Simply stated, it might be that CPZ, when injected acutely, does not affect wheel
running. A second possibility however, could be that the acute WIFS model, which permits only
3 h of daytime wheel access, is not sensitive enough to detect running differences when CPZ is
injected between 0 and 2 mg/kg. Perhaps in future studies, daytime wheel access duration
should be extended. This might allow for running differences to be revealed (or completely
ruled out), while preserving the model's key strength - which is to determine the effect of drugs
on running, feeding and the running feeding interaction.
In the acute WIFS model, it is interesting how little daytime running, around 400 wheel
turns, is necessary to suppress feeding over the subsequent night. This is consistent with
previous work that 2 h of daytime wheel access can suppress feeding as much as ad lib wheel
access (Lattanzio & Eikelboom, 2003) and that no correlation exists between running and the
feeding suppression (Afonso & Eikelboom, 2003). To date, most animal studies of AN have
focused on the effects of food restriction on wheel running in the AA model, which becomes
excessive. The current model however looks directly at the opposite; the effects of limited wheel
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access on feeding. In this case, excessive wheel running is not critical to the model, a
phenomenon that enables us to test the effects of drugs specifically on the running feeding
interaction.

Chlorpromazine's effect of feeding in the acute WIFS
In the present experiments, animals that received a saline or a low dose CPZ injection
(less than 1 mg/kg), either before or after wheel access, were the only animals that showed the
anticipated feeding suppression. At doses equal to or greater than 1 mg/kg, CPZ prevented the
feeding suppression when injected either before or after wheel exposure. That the non-wheel
CPZ injected controls did not eat significantly more than the saline control animals indicates that
the drug, when injected acutely, does not increase appetite or food intake overall. This is
contrary to what is observed when CPZ is administered chronically (Allison et al., 1999).
Reasons for this are unclear. It might be that the effects of CPZ on the serotonin and histamine
systems (and thus feeding and weight gain) change with repeated exposure. To understand what
is happening, researchers will have to identify the physiological changes that accompany chronic
CPZ exposure. Do the feeding centers in the brain become more sensitive to the antagonizing
effects of CPZ? Are specific receptors up or down regulated? Answers to these questions may
be important in helping us understand feeding, and pathologies of feeding.
In the current experiment running did not differ significantly between the groups so it
appears this acute CPZ administration did not decrease activity and in this way circumvent the
WIFS phenomenon.

Results from Experiment 2, our dose-response analysis of CPZ effects on

the acute WIFS, suggest that there may be an 'optimal dose range' that does not significantly
reduce running with acute application, but does prevent the WIFS. Although we cannot confirm
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the upper end of this 'optimal dose range', it appears that 1 mg/kg may be the minimum
required. 2 mg/kg was chosen to mirror previous work with CPZ in AA, in which 2 mg/kg were
used (Routtenberg, 1968; Routtenberg & Kuzeneof, 1967; Woods & Routtenberg, 1971). It
appears that CPZ targets the relationship between feeding and activity in the running wheel,
specifically uncoupling them to avoid the counterintuitive reduction in feeding that often
accompanies running. The exact biochemical mechanisms underlying these results are not yet
clear but hypotheses can be made.

Why might Chlorpromazine prevent the running feeding interaction?
Currently the biological underpinnings of the WIFS are unknown. Based on the present
results however, combined with related literature, a working hypothesis can be deduced. Bouts
of exercise, both voluntary wheel running (Lattanzio & Eikelboom, 2003) and forced treadmill
exercise (Oscal, 1973), are known to increase the activity of the central serotonin (Jacobs, 1994;
Chaouloff, 1997), histamine (Ransford, 1982) and dopamine (Dunn et al., 1996) systems in rats.
Following wheel introduction, rats show a temporary feeding suppression compared to nonrunning controls, a finding that has been consistently reported in AA (Lett & Grant, 2001), WIFS
(Lattanzio & Eikelboom, 2003) and acute WIFS (Adams & Eikelboom, unpublished work)
procedures. From these results it can be proposed that running and feeding may interact via the
serotonin and histamine systems. To investigate this further, more specific agonists and
antagonists need to be tested. Running may cause a feeding suppression through the release of
serotonin and histamine, which in turn act on the 5-HT2C and HI receptors, respectively, to
reduce appetite and food intake. This is supported by the widely accepted notion that 5-HT and
histamine pathways play a fundamental role in energy balance (Vickers et al., 2000). Dopamine
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is also released during wheel running (Dunn et al., 1996) and may play a significant role in
reinforcing these maladaptive behaviours, encouraging them to potentially propagate to
dangerous levels, like in the model AA or AN itself.
If this theory is accurate it may explain how CPZ acts to specifically prevent the feeding
suppression in the acute WIFS model. At doses of 1-2 mg/kg, CPZ potentially antagonizes the
5HT2C and HI receptors, enough to counteract the suppressive effects of running on appetite and
feeding, but not enough to increase feeding in the drug injected non-running control rats. The
antidopaminergic properties of CPZ might also have helped by reducing the rewarding aspects of
engaging in these counterintuitive behaviours. This framework then, highlights at least three
systems that may potentially be involved in the WIFS, AA and AN.
To identify more specifically the potential roles of the serotonin, histamine and dopamine
systems in the WIFS, future work could test drugs that act specifically on a single receptor type
in the acute WIFS paradigm. For example, it would be interesting to independently test the
effects of the specific 5-HT2C serotonin antagonist SB-242084 (Kennett et al, 1997), the
dopamine D2 receptor blocker pimozide (Lambert & Porter, 1992), and the HI receptor
antagonist doxepin (Kanba & Richelson, 1983) to see how each of these would effect running
and feeding in the acute WIFS model. Results from such studies would indicate which receptor,
or combination of receptors, is important in preventing the interaction between running and
feeding in rats. This in turn could help uncover the neurochemical substrates of the WIFS and
potentially AN.
It should be noted that the above explanation presents a simplified view of the complex
biochemical reactions that likely take place in the WIFS, AA and AN. The purpose of this
discussion is to provide a foundation on which future hypotheses can be tested. There are likely
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many factors and neurochemical systems contributing to the counterintuitive relationship that
sometimes exists between feeding and exercise, only a few of which are touched on here.

Future Avenues of Exploration
To date, most clinical therapies of AN involve the administration of selective serotonin
reuptake inhibitors, which are effective in treating the psychopathology but are ineffective in
producing weight gain (Bergh et al., 1996). These results are puzzling, especially since 5-HT2C
receptor antagonists are known to induce weight gain in non-anorexic humans (Meguid, Fetissov
& Verma, 2000), and suggest that serotonin may not play a major role in linking exercise to
feeding, at least in underweight AN patients. It would be interesting to test the effects of specific
serotonin reuptake inhibitors on feeding and wheel running in the acute WIFS model. Results
from such studies would help increase the models validity if they paralleled those observed in a
human clinical setting.
A more interesting direction however, might be to test the effects of specific HI
antagonists on the acute WIFS. Results from this work may implicate the central histamine
system as being the major biological link between feeding and exercise in wheel running rats,
and potentially AN. The central histamine system has long been implicated in feeding. Central
histaminergic activity is increased by food intake after starvation (Itoh, Oishi & Saeki, 1991) and
HI receptor concentration is correlated with food intake, particularly in low protein diets
(Mercer, et al. 1994). Interestingly, AN patients have recently been found to have higher central
HI receptor densities compared to that of healthy controls participants (Yoshizawa et al., 2009).
Identifying the effects of specific HI antagonists on rats in the acute WIFS model could help
validate the model and lead researchers to explore this exciting avenue.
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The current experiment using the WIFS model involved acute, one time exposure to the
drug, prior to application of an AN model. While the acute condition is valuable for screening
this and other drugs for effectiveness, in reality, these drugs would be given chronically to
humans. Thus, further study involving chronic access to CPZ and repeated access to the wheel is
needed.
Prior work has suggested that 2 h a day of daytime wheel access produces a feeding
suppression that lasts for 7 to 10 days (Lattanzio & Eikelboom, 2003), so this experimental
protocol can be used to test drugs in a more chronic application. Also, rats could be injected
with CPZ (or the drug of interest) several days before wheel access, a strategy that has been used
effectively in the past (Routtenberg, 1968). Based on the early work (Routtenberg, 1968;
Routtenberg & Kuzeneof, 1967; Woods & Routtenberg, 1971), it might be expected that with a
higher CPZ dose or chronic administration of the drug, that the drug before and drug after wheel
groups might differ in wheel running.

Conclusions
The present study suggests that injections of CPZ can eliminate the negative interaction
between feeding and exercise observed in the acute WIFS preparation. Although these finding
may prove helpful in identifying the neurochemical substrates of the WIFS and ultimately AN,
they may raise more questions than answers. For example, although we have discovered that
CPZ prevents the WIFS, the specific neurochemical actions of the drug that cause this effect can
only be speculated upon. Here we have described the potential role of the serotonin, histamine
and dopamine systems, the first two of which are linked to feeding and the latter to motivation
and reward. Currently, it is not clear if it is CPZ's effect on one, two or all three of these systems
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that is important in preventing the WIFS. To understand this, multiple studies would need to be
conducted testing a battery of drugs that bind to a specific complement of these receptors. This
would allow researchers to determine which receptors and brain regions are important in
preventing the negative interaction between feeding and running observed in wheel running rats
(and potentially in AN). Furthermore, once a drug has been identified that specifically acts on
the receptors sites involved in the WIFS, researchers will have to investigate the effects of
chronically administering this drug. Also, as AN is predominantly observed in women, our
results need to be replicated in female rats.
The current experiments suggest that the acute WIFS paradigm may act as a legitimate
"drug screening" model for AN but there are many challenges ahead. To develop this model
further would require a massive time commitment and money investment. Although the
resources to continue this work are not currently available, the goal of this project was to identify
the potential for an acute "pre-clinical" rat model of AN to give us insight on how to treat
patients more effectively.
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Figure Captions
Figure 1. Mean (±SEM) wheel turns over the initial 24 h wheel exposure. Animals were
assigned to the chlorpromazine-wheel (DW), wheel-chlorpromazine (WD), saline-wheel (SW),
chlorpromazine-locked wheel (DNW) and saline-locked wheel (SNW) groups to balance for
distance run.

Figure 2. Mean (±SEM) food consumption (g) over the 24 h before (PreWheel) and after
(PostWheel) the initial 24 h wheel exposure. Rats were assigned to the chlorpromazine-wheel
(DW), wheel-chlorpromazine (WD), saline-wheel (SW), chlorpromazine-locked wheel (DNW)
and saline-locked wheel (SNW) groups based on their level of feeding suppression.

Figure 3. Mean (±SEM) wheel turns (3 h access, paired with an injection). No significant
differences existed between any of the chlorpromazine-wheel (DW), wheel-chlorpromazine
(WD), saline-wheel (SW).

Figure 4. Mean (±SEM) food consumption (g) in the 24 h following chlorpromazine (D) or
saline (S) injection and 3 h of wheel (W) or locked wheel (NW) access. Group DW was injected
before, whereas group WD was injected after wheel access. * Significantly different from other
four groups (NewmanKeuls/><.05).

Figure 5. Mean (±SEM) wheel turns over the initial 24h wheel exposure. The 2 mg/kg
chlorpromazine-wheel (2-DW), wheel-2 mg/kg chlorpromazine (2-WD), 1 mg/kg
chlorpromazine-wheel (1-DW), .50 mg/kg chlorpromazine-wheel (.5-DW), .25 mg/kg
chlorpromazine-wheel (.25-DW), saline-wheel (SW), saline-locked wheel (SNW) and 2 mg/kg
chlorpromazine-locked wheel (2-DNW) groups were balanced for distance run.

Figure 6. Mean (±SEM) food consumption (g) before (PreWheel) and after (PostWheel) the
initial 24 h wheel access. The 2 mg/kg chlorpromazine-wheel (2-DW), wheel-2 mg/kg
chlorpromazine (2-WD), 1 mg/kg chlorpromazine-wheel (1-DW), .50 mg/kg chlorpromazine-
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wheel (.5-DW), .25 mg/kg chlorpromazine-wheel (.25-DW), saline-wheel (SW), saline-locked
wheel (SNW) and 2 mg/kg chlorpromazine-locked wheel (2-DNW) groups were balanced for
their level of feeding suppression.

Figure 7. Mean (±SEM) wheel turns (3 h access paired with an injection) No significant
differences between the 2 mg/kg chlorpromazine-wheel (2-DW), wheel-2 mg/kg chlorpromazine
(2-WD), 1 mg/kg chlorpromazine-wheel (1-DW), .50 mg/kg chlorpromazine-wheel (.5-DW), .25
mg/kg chlorpromazine-wheel (.25-DW), saline-wheel (SW).

Figure 8. Mean (SEM) food consumption (g) in the 24 h following chlorpromazine (D) or saline
(S) injection and 3 h of wheel (W) or locked wheel (NW) access. Group DW was injected
before, whereas group WD was injected after wheel access. The SW group consumed
* significantly less then all groups except the 5-WD and .25-WD (which consumed intermediate
amounts, statistically equal to all other groups) as per the NewmanKeuls post hoc, p<.05.
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Figure 3
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Figure 4
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Figure 5
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Figure 6

Food Consumption
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Figure 7
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Figure 8

Food Consumption
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